Vir Biotechnology (NASDAQ:VIR) Director Sells $130,460.00 in Stock

Vir Biotechnology, Inc. (NASDAQ:VIR) Director Vicki Sato sold 22,000 shares of the firm’s stock in a transaction dated Friday, January 2nd. The shares were sold at an average price of $5.93, for a total transaction of $130,460.00. Following the completion of the transaction, the director directly owned 1,166,391 shares in the company, valued at approximately $6,916,698.63. The trade was a 1.85% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Vir Biotechnology Stock Up 3.4%

Shares of VIR stock opened at $6.16 on Thursday. The firm has a market cap of $856.98 million, a P/E ratio of -1.71 and a beta of 1.39. The company has a 50 day moving average of $5.98 and a 200-day moving average of $5.54. Vir Biotechnology, Inc. has a 12-month low of $4.16 and a 12-month high of $14.45.

Vir Biotechnology (NASDAQ:VIR) last issued its earnings results on Wednesday, November 5th. The company reported ($1.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.47). Vir Biotechnology had a negative return on equity of 50.76% and a negative net margin of 2,963.54%.The business had revenue of $0.24 million for the quarter, compared to the consensus estimate of $1.98 million. During the same quarter in the prior year, the business earned ($1.56) EPS. Vir Biotechnology’s revenue for the quarter was up .8% compared to the same quarter last year. As a group, equities analysts expect that Vir Biotechnology, Inc. will post -3.92 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on VIR. Weiss Ratings reissued a “sell (d-)” rating on shares of Vir Biotechnology in a research note on Monday, December 22nd. HC Wainwright reaffirmed a “buy” rating and set a $15.00 price objective on shares of Vir Biotechnology in a research report on Tuesday, December 30th. Nine analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $17.30.

Institutional Trading of Vir Biotechnology

Several large investors have recently bought and sold shares of VIR. ARCH Venture Management LLC acquired a new position in shares of Vir Biotechnology in the 2nd quarter valued at about $65,100,000. Orbimed Advisors LLC increased its position in Vir Biotechnology by 5.9% during the second quarter. Orbimed Advisors LLC now owns 2,380,715 shares of the company’s stock worth $11,999,000 after purchasing an additional 132,466 shares during the last quarter. Aberdeen Group plc raised its stake in Vir Biotechnology by 51.6% during the third quarter. Aberdeen Group plc now owns 1,526,265 shares of the company’s stock worth $8,715,000 after purchasing an additional 519,374 shares during the period. Millennium Management LLC lifted its holdings in Vir Biotechnology by 129.2% in the third quarter. Millennium Management LLC now owns 1,396,504 shares of the company’s stock valued at $7,974,000 after acquiring an additional 787,212 shares during the last quarter. Finally, Hudson Bay Capital Management LP increased its stake in Vir Biotechnology by 31.0% during the third quarter. Hudson Bay Capital Management LP now owns 911,882 shares of the company’s stock worth $5,207,000 after acquiring an additional 215,882 shares during the last quarter. Hedge funds and other institutional investors own 65.32% of the company’s stock.

About Vir Biotechnology

Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.